MAP2K7 and neoplasm: It has been documented that small molecule inhibitors (vemurafenib and dabrafenib) of BRAF V600–mutant induce tumor regression, and combination of BRAF and MEK inhibitors can improve survival rate of melanoma patients [32–34].